Published in Nat Rev Neurosci on July 31, 2013
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci (2015) 1.52
An Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity. PLoS One (2016) 1.40
Plasma α-synuclein predicts cognitive decline in Parkinson's disease. J Neurol Neurosurg Psychiatry (2017) 1.39
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci (2014) 1.04
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol (2015) 1.02
Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener (2014) 1.00
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation. Proc Natl Acad Sci U S A (2015) 0.91
A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat Commun (2015) 0.91
Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons. Mol Biol Cell (2014) 0.91
Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proc Natl Acad Sci U S A (2014) 0.91
Unlike twins: an NMR comparison of two α-synuclein polymorphs featuring different toxicity. PLoS One (2014) 0.91
Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol (2015) 0.89
A common gene expression signature in Huntington's disease patient brain regions. BMC Med Genomics (2014) 0.88
Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules (2015) 0.88
Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord (2014) 0.88
Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis (2014) 0.87
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther (2014) 0.86
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol (2016) 0.86
DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death Dis (2014) 0.85
Tau acts as a mediator for Alzheimer's disease-related synaptic deficits. Eur J Neurosci (2014) 0.85
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci (2016) 0.84
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci (2015) 0.84
Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer. J Clin Neurol (2016) 0.83
Detection of ubiquitinated huntingtin species in intracellular aggregates. Front Mol Neurosci (2015) 0.83
Drosophila as an In Vivo Model for Human Neurodegenerative Disease. Genetics (2015) 0.83
Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. J Neurol Neurosurg Psychiatry (2016) 0.82
GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ (2014) 0.82
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc Natl Acad Sci U S A (2016) 0.82
Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. Acta Neuropathol Commun (2013) 0.82
Parkinson disease and progressive supranuclear palsy: protein expression in skin. Ann Clin Transl Neurol (2016) 0.82
18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain (2017) 0.81
An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS One (2016) 0.81
Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease. Mov Disord (2015) 0.81
β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics (2015) 0.80
A novel fizzy/Cdc20-dependent mechanism suppresses necrosis in neural stem cells. Development (2014) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Retracted β-Amyloid and α-synuclein cooperate to block SNARE-dependent vesicle fusion. Biochemistry (2015) 0.79
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol (2016) 0.79
What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? Exp Neurobiol (2014) 0.79
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets (2014) 0.79
Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl Psychiatry (2016) 0.78
Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease. Front Neurol (2015) 0.78
Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies. Sci Rep (2016) 0.78
The Mental Status Examination in Patients With Suspected Dementia. Continuum (Minneap Minn) (2016) 0.78
Precision Modulation of Neurodegenerative Disease-Related Gene Expression in Human iPSC-Derived Neurons. Sci Rep (2016) 0.78
Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnology (2016) 0.78
Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism Relat Disord (2016) 0.78
Acteoside Binds to Caspase-3 and Exerts Neuroprotection in the Rotenone Rat Model of Parkinson's Disease. PLoS One (2016) 0.77
Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One (2015) 0.77
Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin. Hum Mol Genet (2014) 0.77
Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease. Brain (2015) 0.77
Cross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study. PLoS One (2014) 0.77
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol (2017) 0.77
Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity. Neural Plast (2014) 0.77
Cognitive decline in Parkinson disease. Nat Rev Neurol (2017) 0.77
High-speed atomic force microscopy reveals structural dynamics of amyloid β1-42 aggregates. Proc Natl Acad Sci U S A (2016) 0.76
The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. Psychiatr Clin North Am (2015) 0.76
MiR-144-3p and Its Target Gene β-Amyloid Precursor Protein Regulate 1-Methyl-4-Phenyl-1,2-3,6-Tetrahydropyridine-Induced Mitochondrial Dysfunction. Mol Cells (2016) 0.76
Dynamic Trk and G Protein Signalings Regulate Dopaminergic Neurodifferentiation in Human Trophoblast Stem Cells. PLoS One (2015) 0.76
Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiol Dis (2016) 0.76
A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol (2017) 0.75
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. J Mov Disord (2016) 0.75
Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry. Neuroimage Clin (2016) 0.75
Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's Disease. PLoS One (2016) 0.75
Synuclein expression in the lizard Anolis carolinensis. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2016) 0.75
Fish Synucleins: An Update. Mar Drugs (2015) 0.75
Formation of neurodegenerative aggresome and death-inducing signaling complex in maternal diabetes-induced neural tube defects. Proc Natl Acad Sci U S A (2017) 0.75
Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology (2016) 0.75
Propagated but Topologically Distributed Forebrain Neurons Expressing Alpha-Synuclein in Aged Macaques. PLoS One (2016) 0.75
Integrated multimodal imaging in neurodegenerative disease. Lancet Neurol (2015) 0.75
Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. Int J Mol Sci (2017) 0.75
Modeling Idiopathic Parkinson Disease as a Complex Illness Can Inform Incidence Risk in Healthy Adults: The PR EDIGT Score. Eur J Neurosci (2016) 0.75
Identification of a specific α-synuclein peptide (α-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. J Neuroinflammation (2016) 0.75
Nanomolar oligomerization and selective co-aggregation of α-synuclein pathogenic mutants revealed by single-molecule fluorescence. Sci Rep (2016) 0.75
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Neuropsychol Rev (2015) 0.75
Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res (2017) 0.75
Neuropsychiatric Symptoms in Parkinson's Disease Dementia Are More Similar to Alzheimer's Disease than Dementia with Lewy Bodies: A Case-Control Study. PLoS One (2016) 0.75
Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. Front Hum Neurosci (2017) 0.75
Opening up the DNA methylome of dementia. Mol Psychiatry (2017) 0.75
Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity. PLoS One (2015) 0.75
Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (2016) 0.75
Back to the tubule: microtubule dynamics in Parkinson's disease. Cell Mol Life Sci (2016) 0.75
Peripheral vagus nerve stimulation significantly affects lipid composition and protein secondary structure within dopamine-related brain regions in rats. Neuromolecular Med (2015) 0.75
Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cells. PLoS One (2017) 0.75
Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol (2017) 0.75
Perspective: Neuroregenerative Nutrition. Adv Nutr (2017) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol (1994) 5.20
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology (2005) 3.29
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology (2003) 3.07
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol (2000) 2.91
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol (2008) 2.78
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol (2002) 2.70
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron (2006) 2.66
The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol (2011) 2.65
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol (2002) 2.46
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis (2006) 2.41
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Research diagnostic criteria for Parkinson's disease. Adv Neurol (1990) 2.28
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology (2013) 2.24
Clinical phenotype of Parkinson disease dementia. Neurology (2006) 2.22
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol (2005) 2.21
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging (2011) 2.18
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology (2006) 2.17
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol (1983) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol (2007) 1.92
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (2002) 1.90
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol (2012) 1.86
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology (2005) 1.82
The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol (2008) 1.80
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci (2011) 1.79
Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med (1985) 1.75
Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol (2005) 1.74
Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna) (2004) 1.74
Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol (2008) 1.74
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology (1999) 1.70
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord (2012) 1.69
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol (2003) 1.59
Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (2011) 1.57
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009) 1.54
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology (2005) 1.52
Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord (2002) 1.52
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell (2005) 4.25
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol (2005) 4.00
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem (2008) 3.56
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (2010) 3.16
Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol (2006) 3.01
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76